Nanoemulsion-based mucosal adjuvant induces apoptosis in human epithelial cells

Vaccine

Volumn 33, Issue 19, 2015, Pages 2289-2296

  Orzechowska, Beata U ^a   Kukowska Latallo, Jolanta F ^b   Coulter, Alexa D ^c   Szabo, Zsuzsanna ^c   Gamian, Andrzej ^a,e   Myc, Andrzej ^a,b,d  

^a INSTITUTE OF IMMUNOLOGY AND EXPERIMENTAL THERAPY   (Poland)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF ZIELONA GÓRA   (Poland)

^e WROCLAW RESEARCH CENTRE EIT   (Poland)

Author keywords

Autophagy; Caspases; FaDu; Necroptosis; Necrosis; Pyroptosis; RPMI 2650

Indexed keywords

ADJUVANT; ANTIGEN; CASPASE 3; CASPASE 6; CASPASE 7; CASPASE 8; CASPASE 9; INTERLEUKIN 1BETA CONVERTING ENZYME; STAUROSPORINE; EMULSION; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL DEATH; CONTROLLED STUDY; DENDRITIC CELL; ENZYME ACTIVATION; EPITHELIUM CELL; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPH NODE; NANOEMULSION; PRIORITY JOURNAL; CELL LINE; DRUG EFFECTS; EMULSION; PHYSIOLOGY; TOXICITY;

ADJUVANTS, IMMUNOLOGIC; APOPTOSIS; CELL LINE; EMULSIONS; EPITHELIAL CELLS; HUMANS; NANOPARTICLES;

EID: 84933279152     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2015.03.002     Document Type: Article

References (40)

1. Israeli E., Agmon-Levin N., Blank M., Shoenfeld Y. Adjuvants and autoimmunity. Lupus 2009, 18(13):1217-1225.
2. Braun L.J., Eldridge A.M., Cummiskey J., Arthur K.K., Wuttke D.S. The role of adjuvant in mediating antigen structure and stability. J Pharm Sci 2012, 101(4):1391-1399.
3. Garcon N., Chomez P., Van Mechelen M. GlaxoSmithKline Adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev Vaccines 2007, 6(5):723-739.
4. Leroux-Roels G. Unmet needs in modern vaccinology: adjuvants to improve the immune response. Vaccine 2010, 28:C25-C36.
5. Shoenfeld Y., Agmon-Levin N. 'ASIA' - autoimmune/inflammatory syndrome induced by adjuvants. J Autoimmun 2011, 36(1):4-8.
6. Perricone C., Colafrancesco S., Mazor R.D., Soriano A., Agmon-Levin N., Shoenfeld Y. Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) 2013: Unveiling the pathogenic, clinical and diagnostic aspects. J Autoimmun 2013, 47:1-16.
7. Ahmed S.S., Schur P.H., MacDonald N.E., Steinman L. Narcolepsy, 2009 A(H1N1) pandemic influenza, and pandemic influenza vaccinations: what is known and unknown about the neurological disorder, the role for autoimmunity, and vaccine adjuvants. J Autoimmun 2014, 50:1-11.
8. Makidon P.E., Bielinska A.U., Nigavekar S.S., Janczak K.W., Knowlton J., Scott A.J., et al. Pre-clinical evaluation of a novel nanoemulsion-based hepatitis B mucosal vaccine. PLoS ONE 2008, 3(8):e2954.
9. Bielinska A.U., Chepurnov A.A., Landers J.J., Janczak K.W., Chepurnova T.S., Luker G.D., et al. A novel: killed-virus nasal vaccinia virus vaccine. Clin Vaccine Immunol 2008, 15(2):348-358.
10. Bielinska A.U., Janczak K.W., Landers J.J., Makidon P., Sower L.E., Peterson J.W., et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 2007, 75(8):4020-4029.
11. Bielinska A.U., Janczak K.W., Landers J.J., Markovitz D.M., Montefiori D.C., Baker J.R. Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. AIDS Res Hum Retrovir 2008, 24(2):271-281.
12. Hamouda T., Chepurnov A., Mank N., Knowlton J., Chepurnova T., Myc A., et al. Efficacy: immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum Vaccin 2010, 6(7):585-594.
13. Lindell D.M., Morris S.B., White M.P., Kallal L.E., Lundy P.K., Hamouda T., et al. A novel inactivated intranasal respiratory syncytial virus vaccine promotes viral clearance without Th2 associated vaccine-enhanced disease. PLoS ONE 2011, 6(7):e21823.
14. Makidon P.E., Knowlton J., Groom J.V., Blanco L.P., LiPuma J.J., Bielinska A.U., et al. Induction of immune response to the 17kDa OMPA Burkholderia cenocepacia polypeptide and protection against pulmonary infection in mice after nasal vaccination with an OMP nanoemulsion-based vaccine. Med Microbiol Immunol 2010, 199(2):81-92.
15. Myc A., Kukowska-Latallo J.F., Bielinska A.U., Cao P., Myc P.P., Janczak K., et al. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine 2003, 21(25-26):3801-3814.
16. Zitvogel L., Kepp O., Senovilla L., Menger L., Chaput N., Kroemer G. Immunogenic tumor cell death for optimal anticancer therapy: the calreticulin exposure pathway. Clin Cancer Res 2010, 16(12):3100-3104.
17. Bielinska A.U., Gerber M., Blanco L.P., Makidon P.E., Janczak K.W., Beer M., et al. Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. Crit Rev Immunol 2010, 30(2):189-199.
18. 805EC combined with approved seasonal influenza antigens. Vaccine 2012, 30(2):307-316.
19. 805EC induces dendritic cell engulfment of antigen-primed epithelial cells. Vaccine 2013, 31(7):1072-1079.
20. Albert M.L., Sauter B., Bhardwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998, 392(6671):86-89.
21. Hirt U.A., Leist M. Rapid, noninflammatory and PS-dependent phagocytic clearance of necrotic cells. Cell Death Differ 2003, 10(10):1156-1164.
22. Gallucci S., Lolkema M., Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999, 5(11):1249-1255.
23. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25(4):402-408.
24. Lohmann C., Muschaweckh A., Kirschnek S., Jennen L., Wagner H., Hacker G. Induction of tumor cell apoptosis or necrosis by conditional expression of cell death proteins: analysis of cell death pathways and in vitro immune stimulatory potential. J Immunol 2009, 182(8):4538-4546.
25. Lecoeur H., Prevost M.C., Gougeon M.L. Oncosis is associated with exposure of phosphatidylserine residues on the outside layer of the plasma membrane: a reconsideration of the specificity of the annexin V/propidium iodide assay. Cytometry 2001, 44(1):65-72.
26. Makidon P.E., Belyakov I.M., Janczak K.W., Lenders J., Bielinska A.U., Groom J.V., et al. Nanoemulsion mucosal adjuvant uniquely activates cytokine production be nasal ciliated epithelium and induces dendritic cells trafficking. Eur J Immunol 2012, 42(8):2073-2086.
27. Fink S.L., Cookson B.T. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun 2005, 73(4):1907-1916.
28. Boise L.H., Collins C.M. Salmonella-induced cell death: apoptosis, necrosis or programmed cell death?. Trends Microbiol 2001, 9(2):64-67.
29. Hueffer K., Galan J.E. Salmonella-induced macrophage death: multiple mechanisms, different outcomes. Cell Microbiol 2004, 6(11):1019-1025.
30. Gunther C., Martini E., Wittkopf N., Amann K., Weigmann B., Neumann H., et al. Caspase-8 regulates TNF-alpha-induced epithelial necroptosis and terminal ileitis. Nature 2011, 477(7364):335-339.
31. Panaretakis T., Kepp O., Brockmeier U., Tesniere A., Bjorklund A.C., Chapman D.C., et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009, 28(5):578-590.
32. Yang Y.W., Shen S.S. Enhanced antigen delivery via cell death induced by the vaccine adjuvants. Vaccine 2007, 25(45):7763-7772.
33. Yang Y.W., Wu C.A., Morrow W.J. The apoptotic and necrotic effects of tomatine adjuvant. Vaccine 2004, 22(17-18):2316-2327.
34. Yang Y.W., Wu C.A., Morrow W.J. Cell death induced by vaccine adjuvants containing surfactants. Vaccine 2004, 22(11-12):1524-1536.
35. Sauter B., Albert M.L., Francisco L., Larsson M., Somersan S., Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000, 191(3):423-434.
36. Albert M.L., Pearce S.F., Francisco L.M., Sauter B., Roy P., Silverstein R.L., et al. Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36: and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 1998, 188(7):1359-1368.
37. Salmon M., Gordon C. The role of apoptosis in systemic lupus erythematosus. Rheumatology 1999, 38(12):1177-1183.
38. Waite J.C., Skokos D. Th17 response and inflammatory autoimmune diseases. Int J Inflam 2012, 2012:819467.
39. H) 17 cells as a double-edged sword in the interplay of infection and autoimmunity with a focus on xenobiotic-induced immunomodulation. Clin Dev Immunol 2013, 2013:1-13. Article ID 374769. 10.1155/2013/374769.
40. Morel L. Mouse models of human autoimmune diseases: essential tools that require the proper controls. PLoS Biol 2004, 2(8):1061-1064.